Clinical Trial Update: Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects [Phase 1]

View source ↗

Summary

A completed Phase 1 pharmacokinetic study evaluating absorption, metabolism, and elimination of SAM-531 (14-Carbon-SAM-531) in male subjects, as part of Alzheim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SAM-531 (14-Carbon)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED